ArticleInternational urology and nephrology2026
Impact of a new diagnostic pathway for prostate cancer-from systematic transrectal to targeted MRI fusion transperineal biopsies.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Diagnostic Performance of Perineal MRI-US Fusion Prostate Biopsy: A Single-Center Prospective Cohort Analysis.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdvancements in prostate cancer diagnostics have changed the diagnostic pathway from traditional ultrasound-guided systematic transrectal biopsies to pre-biopsy prostate multiparametric MRI and targeted transperineal biopsies. This study aims to determine changes in prostate cancer detection rates, clinical outcomes, and treatment before (2018) and after (2023) implementing the new diagnostic pathway.
methodsThis retrospective study comprises two cohorts from two Danish hospitals-one from 2018 (n = 266) and one from 2023 (n = 304). In each cohort, men with suspected prostate cancer who underwent biopsies were analysed. Data were obtained from medical records. Categorical variables were compared using Chi-square or Fisher's exact test. Continuous variables were analysed with the Mann-Whitney U test in STATA version 18. P value ≤ 0.05 was considered significant.
resultsThe 2023 cohort showed a significantly higher detection of clinically significant prostate cancer (Gleason ≥ 3 + 4) compared to the 2018 cohort (65.41% vs. 41%, p < 0.01). Median Gleason scores increased from 6 to 7 (IQR 6-7 vs. 6-8, p < 0.01). Hospital admissions decreased from 11.3% to 3% (p < 0.01) in the 2023 cohort. Treatment and D'Amico's risk groups showed no significant changes. Limitations include potential selection bias from only including biopsied patients and findings limited to two Danish hospitals, reducing generalizability.
conclusionTransitioning to targeted transperineal biopsies improved cancer detection and reduced complications. While the Gleason score increased, risk groups and treatment plans remained unchanged. These results support implementation in clinical practice, though further studies are needed to assess long-term outcomes and broader applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.